TCG Crossover is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies.
TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 31, 2021
Entrada Therapeutics
|
Series B | $116M | Biotechnology | — |